New Clinical Findings Show Promising Improvement in Melasma in Fitzpatrick V Skin
LOUISVILLE, Ky., Sept. 9, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
New Clinical Findings Show Promising Improvement in Melasma in Fitzpatrick V Skin
PR Newswire
LOUISVILLE, Ky., Sept. 9, 2026
Visible improvement observed in longstanding melasma following a tailored Collagen P.I.N.® + PRX8 treatment protocol
LOUISVILLE, Ky., Sept. 9, 2026 /PRNewswire/ — Induction Therapies, innovators in aesthetics and advanced microneedling technology, and Collagen P.I.N.®, in partnership with renowned aesthetic physician Dr. Shino Bay Aguilera, announced new clinical findings evaluating a treatment protocol combining Collagen P.I.N.® microneedling with PRX8, a plant-derived exosome product, for the appearance of melasma in Fitzpatrick skin type V.
The evaluation followed a woman with Fitzpatrick skin type V and longstanding facial melasma who had previously used topical hydroquinone and tranexamic acid. She received four Collagen P.I.N. treatments over eight weeks, with TRUExosomes PRX8 Plant-Exo Stimulation Serum applied after each treatment and daily sunscreen use maintained throughout the protocol. Visible improvement in the appearance of melasma was observed throughout the treatment course and continued at the final two-week follow-up after the fourth treatment with no adverse reactions reported.
“What makes these findings particularly compelling is what they underscore about treating pigmentation concerns in skin of color: technique, customization and clinical judgment matter,” said Dr. Shino Bay Aguilera. “The combination of Collagen P.I.N.® and PRX8 also gives us an opportunity to evaluate how these modalities may work together as part of a comprehensive treatment protocol, rather than viewing PRX8 simply as a topical product.”
“We know that patients are looking for effective, evidence-informed options that take their skin type into account,” said Angelia Inscoe, Founder of Induction Therapies® and Collagen P.I.N. “These findings are encouraging because they highlight the importance of thoughtful treatment protocols and appropriately performed microneedling, while contributing to the broader conversation around how we can continue advancing aesthetic care for diverse patients.”
These findings advance the understanding of properly performed microneedling and combination treatment approaches across diverse skin types, reinforcing the importance of personalized protocols and clinician expertise in optimizing patient outcomes.
The full study can be found here. For more information, please visit inductiontherapies.com and collagenpin.com.
About Induction Therapies® | Collagen P.I.N.®
Induction Therapies is a clinically driven aesthetics company redefining how treatments, skincare, and outcomes work together. Founded by industry veteran and serial entrepreneur, Angelia Inscoe, the brand was built on a simple but often overlooked truth: meaningful results don’t come from a single product or procedure — they come from a system.
At the center of this philosophy is the Collagen P.I.N.® microneedling device, the first of its kind to introduce an industry-leading 36-pin needle cartridge and precision depth up to 3.0mm, expanding what microneedling can achieve in both performance and versatility. Engineered to create more microchannels with greater control, it delivers enhanced collagen stimulation, deeper product absorption, and more consistent, high-performance outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-clinical-findings-show-promising-improvement-in-melasma-in-fitzpatrick-v-skin-302873376.html
SOURCE Collagen P.I.N.



